LGM
Logos Global Management Portfolio holdings
AUM
$749M
This Quarter Return
+5.39%
1 Year Return
+18.94%
3 Year Return
+431.72%
5 Year Return
+481.1%
10 Year Return
–
AUM
$749M
AUM Growth
+$749M
(+33%)
Cap. Flow
+$23.7M
Cap. Flow
% of AUM
3.17%
Top 10 Holdings %
Top 10 Hldgs %
54.66%
Holding
60
New
18
Increased
9
Reduced
11
Closed
12
Top Buys
| 1 |
Jazz Pharmaceuticals
JAZZ
|
$47.8M |
| 2 |
Biogen
BIIB
|
$25.1M |
| 3 |
United Therapeutics
UTHR
|
$24.4M |
| 4 |
Arvinas
ARVN
|
$24.3M |
| 5 |
Neurocrine Biosciences
NBIX
|
$18.9M |
Top Sells
| 1 |
CBIO
Crescent Biopharma, Inc. Common Stock
CBIO
|
$78.2M |
| 2 |
Nuvalent
NUVL
|
$35.5M |
| 3 |
Teva Pharmaceuticals
TEVA
|
$26.1M |
| 4 |
Unicycive Therapeutics
UNCY
|
$22M |
| 5 |
Xenon Pharmaceuticals
XENE
|
$21.8M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
IDEAYA Biosciences
IDYA
$2.15B
| $70.3M | 7.78% | 3,345,000 -155,000 | -4% | -$3.26M |
|
2
Akero Therapeutics
AKRO
$3.74B
| $64M | 7.08% | 1,200,000 | – | – |
|
3
Revolution Medicines
RVMD
$7.1B
| $62.5M | 6.92% | 1,700,000 +100,000 | +6% | +$3.68M |
|
|
4
Jazz Pharmaceuticals
JAZZ
$7.75B
| $47.8M | 5.28% | +450,000 | New | +$47.8M |
|
5
Disc Medicine
IRON
$2.07B
| $37.1M | 4.1% | 700,000 +305,658 | +78% | +$16.2M |
|
6
Avidity Biosciences
RNA
$5.99B
| $27M | 2.99% | 950,000 +600,000 | +171% | +$17M |
|
7
Keros Therapeutics
KROS
$618M
| $26.7M | 2.95% | 2,000,000 | – | – |
|
|
8
Biogen
BIIB
$19.4B
| $25.1M | 2.78% | +200,000 | New | +$25.1M |
|
|
9
United Therapeutics
UTHR
$13.8B
| $24.4M | 2.7% | +85,000 | New | +$24.4M |
|
|
10
Arvinas
ARVN
$568M
| $24.3M | 2.69% | +3,300,000 | New | +$24.3M |
|
11
Janux Therapeutics
JANX
$1.37B
| $23.1M | 2.56% | 1,000,000 -650,000 | -39% | -$15M |
|
12
Ocular Therapeutix
OCUL
$2.12B
| $20.4M | 2.26% | 2,200,000 -100,000 | -4% | -$928K |
|
13
Erasca
ERAS
$445M
| $19.1M | 2.11% | 15,000,000 +2,000,000 | +15% | +$2.54M |
|
|
14
Neurocrine Biosciences
NBIX
$13.8B
| $18.9M | 2.09% | +150,000 | New | +$18.9M |
|
15
Dyne Therapeutics
DYN
$1.92B
| $18.1M | 2% | 1,900,000 +1,400,000 | +280% | +$13.3M |
|
16
Immunocore
IMCR
$1.62B
| $18M | 2% | +575,000 | New | +$18M |
|
17
Structure Therapeutics
GPCR
$1.11B
| $17.6M | 1.95% | 850,000 +425,000 | +100% | +$8.81M |
|
18
Madrigal Pharmaceuticals
MDGL
$9.76B
| $15.1M | 1.67% | +50,000 | New | +$15.1M |
|
19
Design Therapeutics
DSGN
$315M
| $14.2M | 1.57% | 4,217,627 | – | – |
|
20
Krystal Biotech
KRYS
$4.27B
| $13.7M | 1.52% | +100,000 | New | +$13.7M |
|
21
Olema Pharmaceuticals
OLMA
$375M
| $13.7M | 1.51% | 3,208,875 | – | – |
|
22
Celldex Therapeutics
CLDX
$1.47B
| $12.2M | 1.35% | +600,000 | New | +$12.2M |
|
23
Biohaven
BHVN
$1.63B
| $9.88M | 1.09% | +700,000 | New | +$9.88M |
|
24
Xencor
XNCR
$580M
| $9.83M | 1.09% | +1,250,000 | New | +$9.83M |
|
25
Praxis Precision Medicines
PRAX
$958M
| $9.46M | 1.05% | +225,000 | New | +$9.46M |
|